Today: 7 February 2026
Subscribe

Tesla stock edges up after hours as robotaxi deadlines, CPI and earnings line up as next tests for TSLA

Tesla stock edges up after hours as robotaxi deadlines, CPI and earnings line up as next tests for TSLA

Tesla shares rose 0.9% to $448.90 in late Monday trading after a report outlined new 2026 plans including robotaxis and the “Cybercab.” More than 61 million shares traded as the S&P 500 and Dow hit record closes. Investors await Tuesday’s U.S. inflation data and Tesla’s Jan. 28 earnings report. Tesla’s annual sales recently fell for a second year, with China’s BYD now the top EV seller.
12 January 2026
···
Meta stock slips after-hours as Zuckerberg rolls out ‘Meta Compute’ AI buildout

Meta stock slips after-hours as Zuckerberg rolls out ‘Meta Compute’ AI buildout

Meta shares fell 1.7% to $641.92 in after-hours trading Monday after CEO Mark Zuckerberg announced the “Meta Compute” AI infrastructure push. The New York Times reported Meta plans to cut about 10% of Reality Labs staff, or roughly 1,500 jobs, as soon as Tuesday. Zuckerberg named Dina Powell McCormick as president and vice chair. Meta has spent over $60 billion on Reality Labs since 2020.
12 January 2026
··
Nvidia stock barely moves after hours as $1 billion Eli Lilly AI lab plan lands

Nvidia stock barely moves after hours as $1 billion Eli Lilly AI lab plan lands

Nvidia and Eli Lilly will invest up to $1 billion over five years in a joint AI drug discovery lab in the San Francisco Bay area, using Nvidia’s latest chips. Nvidia shares closed at $184.88, up 0.01%, and hovered near $184.94 after hours. The exact lab location will be announced in March. Investors are watching TSMC’s earnings report on January 15 and Nvidia’s on February 25.
12 January 2026
···
iRhythm (IRTC) stock drops after JPM update points to $880 million 2026 revenue

iRhythm (IRTC) stock drops after JPM update points to $880 million 2026 revenue

iRhythm shares fell 5.6% to $169.30 in late trading Monday after the company forecast 2026 revenue of $870–$880 million and an adjusted EBITDA margin of 11.5%–12.5%. Investors focused on the lack of detailed cost and margin data, as well as an upcoming corporate name change. About 1.35 million shares traded, with the stock swinging between $157.34 and $179.82. The company’s update remains preliminary.
12 January 2026
··
Lowe’s stock edges higher while Home Depot slips; traders eye Feb. 25 earnings call

Lowe’s stock edges higher while Home Depot slips; traders eye Feb. 25 earnings call

Lowe’s shares rose 1.1% to $270.09 Monday afternoon, outpacing Home Depot, which slipped 0.6%. About 1.9 million Lowe’s shares changed hands as Wall Street steadied after an early dip tied to Fed concerns. Lowe’s next earnings call is set for Feb. 25, with a $1.20 dividend payable Feb. 4 to holders on record Jan. 21. The stock moved within a $263.83–$270.98 range during the session.
12 January 2026
···
Urban Outfitters stock slides despite “record” holiday sales — what spooked URBN shares

Urban Outfitters stock slides despite “record” holiday sales — what spooked URBN shares

Urban Outfitters shares fell 12% after hours Monday despite a 9% rise in holiday sales, as investors worried about profit margins and future demand. The stock touched $70.27 before recovering to $71.49. Apparel stocks broadly declined after weak forecasts from Abercrombie & Fitch and Birkenstock. Urban Outfitters opened 58 new stores and closed seven in the past eleven months.
12 January 2026
··
Marvell stock stalls even as chip ETFs rise — what’s moving MRVL now

Marvell stock stalls even as chip ETFs rise — what’s moving MRVL now

Marvell Technology shares slipped to $83.21 Monday afternoon, lagging a broader chip rally as the iShares Semiconductor ETF rose 0.7% and Broadcom gained 2.5%. Traders are watching Tuesday’s U.S. CPI data and Thursday’s Taiwan Semiconductor earnings for signals on AI demand. Marvell’s next earnings report is expected in early March. The company recently agreed to buy XConn Technologies for about $540 million.
12 January 2026
··
CrowdStrike stock slips on KeyBanc downgrade as 2026 security budget doubts surface

CrowdStrike stock slips on KeyBanc downgrade as 2026 security budget doubts surface

CrowdStrike shares fell 0.6% to $467.84 Monday after KeyBanc downgraded the stock to “Sector Weight,” citing high valuation and uncertain AI-driven security spending in 2026. The company announced a new partnership with Nord Security targeting small and midsize businesses. KeyBanc’s CIO survey suggests security budgets will trail overall IT spending next year. Other software stocks like Okta rose on the news.
12 January 2026
··
Dave Inc stock drops nearly 9% as fintech lenders slide; CPI test looms for DAVE

Dave Inc stock drops nearly 9% as fintech lenders slide; CPI test looms for DAVE

Dave Inc (DAVE.O) shares fell 8.8% to $218.29 Monday after President Trump called for a 10% cap on credit card interest rates, sparking a selloff in credit-sensitive stocks. About 1.1 million Dave shares traded by mid-afternoon. The drop mirrored declines in other fintechs, including Upstart and Affirm. Dave also faces a Justice Department complaint alleging it misled users about fees, which the company disputes.
12 January 2026
··
Arcutis Biotherapeutics stock slides after 2026 ZORYVE sales outlook; June FDA deadline in focus

Arcutis Biotherapeutics stock slides after 2026 ZORYVE sales outlook; June FDA deadline in focus

Arcutis Biotherapeutics shares fell 8.7% to $25.76 Monday after the company set a 2026 net product sales target of $455–$470 million for its ZORYVE franchise. The company reported $99.2 million in net product revenue last quarter and ended September with $191.4 million in cash. Arcutis plans to expand its sales team by 20% and expects key clinical trial data in early 2026. The stock hit a session low of $25.51.
12 January 2026
··
Caris Life Sciences (CAI) stock drops on preliminary 2025 results, Everlywell cancer-screening deal

Caris Life Sciences (CAI) stock drops on preliminary 2025 results, Everlywell cancer-screening deal

Caris Life Sciences shares fell 8.5% to $26.08 in afternoon trading after the company reported preliminary 2025 revenue near $800 million, up 94%, but warned of significant prior-period adjustments. The company also announced a partnership with Everlywell to develop a blood-based early cancer detection test, with more details expected at the JPMorgan Healthcare Conference later Monday.
12 January 2026
··
HealthEquity stock slides nearly 10% after 2027 outlook; JPM conference is next test

HealthEquity stock slides nearly 10% after 2027 outlook; JPM conference is next test

HealthEquity shares fell about 10% Monday after the company issued a cautious initial fiscal 2027 outlook, projecting revenue between $1.38 billion and $1.41 billion and an HSA cash yield near 3.75%. The stock last traded at $84.62, down $9.53. Executives will present at the J.P. Morgan Healthcare Conference on Tuesday. The company reaffirmed its 2026 guidance.
12 January 2026
··
Credo Technology (CRDO) stock climbs as AI-chip trade stays hot; Needham conference next

Credo Technology (CRDO) stock climbs as AI-chip trade stays hot; Needham conference next

Credo Technology shares rose 3.1% to $155.10 Monday, trading as high as $156.43 amid sector gains and anticipation of its Jan. 14 presentation at Needham’s Growth Conference. The company last reported $268 million in quarterly revenue and forecast up to $345 million for the next period. TSMC will report earnings Jan. 15, with investors watching for AI chip demand signals.
12 January 2026
···
Synchrony Financial stock slides on Trump’s 10% credit-card rate cap pitch — what investors watch next

Synchrony Financial stock slides on Trump’s 10% credit-card rate cap pitch — what investors watch next

Synchrony shares fell 8.2% to $79.76 after Donald Trump called for a one-year 10% cap on credit card interest rates, sparking fears of tighter regulation and profit declines. Analysts said such a cap would require congressional approval. Bread Financial, Capital One, and Barclays also saw declines. Separately, Synchrony expanded CareCredit integration with Fiserv’s Clover platform, now reaching over 40,000 providers.
12 January 2026
·
Texas Instruments stock slips as chip ETF firms; investors eye Jan. 27 earnings amid Fed jitters

Texas Instruments stock slips as chip ETF firms; investors eye Jan. 27 earnings amid Fed jitters

Texas Instruments shares slipped 0.2% to $189.85 in Monday afternoon trading, underperforming chip sector peers as the iShares Semiconductor ETF rose 0.7% and Nvidia gained about 1%. Investors are watching TI’s Jan. 27 earnings for signals on industrial and auto demand amid market volatility tied to a Justice Department probe involving Fed Chair Jerome Powell.
12 January 2026
····
1 … 429 430 431 432 433 … 1,631

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Go toTop